{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:46:13Z","timestamp":1784767573639,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-21735-2","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:05:01Z","timestamp":1738904701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Burden of benign prostatic hyperplasia in the Middle East and North Africa Region, 1990\u20132021"],"prefix":"10.1186","volume":"25","author":[{"given":"Saeid","family":"Safiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikrettin","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J. M.","family":"Sullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Shekarriz-Foumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali-Asghar","family":"Kolahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"4","key":"21735_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/JU.0000000000001298","volume":"204","author":"JK Parsons","year":"2020","unstructured":"Parsons JK, Dahm P, K\u00f6hler TS, Lerner LB, Wilt TJ. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. J Urol. 2020;204(4):799\u2013804.","journal-title":"J Urol"},{"key":"21735_CR2","unstructured":"Awedew, Atalel Fentahun, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.\u00a0Lancet Healthy Longev. 2022;3(11):e754\u201376."},{"issue":"3","key":"21735_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474\u20139.","journal-title":"J Urol"},{"issue":"2","key":"21735_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.juro.2008.10.025","volume":"181","author":"ET Kok","year":"2009","unstructured":"Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol. 2009;181(2):710\u20136.","journal-title":"J Urol"},{"issue":"11","key":"21735_CR5","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1007\/s00345-020-03101-6","volume":"38","author":"I Metzler","year":"2020","unstructured":"Metzler I, Bayne D, Chang H, Jalloh M, Sharlip I. Challenges facing the urologist in low- and middle-income countries. World J Urol. 2020;38(11):2987\u201394.","journal-title":"World J Urol"},{"issue":"5","key":"21735_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1476-5381.2011.01332.x","volume":"163","author":"S Ventura","year":"2011","unstructured":"Ventura S, Oliver V, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol. 2011;163(5):891\u2013907.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"21735_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1464-410X.2007.06609.x","volume":"99","author":"C Robertson","year":"2007","unstructured":"Robertson C, Link CL, Onel E, Mazzetta C, Keech M, Hobbs R, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int. 2007;99(2):347\u201354.","journal-title":"BJU Int"},{"issue":"1","key":"21735_CR8","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1038\/s41598-017-06628-8","volume":"7","author":"SWH Lee","year":"2017","unstructured":"Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep. 2017;7(1):7984.","journal-title":"Sci Rep"},{"issue":"3","key":"21735_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289\u201397.","journal-title":"Urol Clin North Am"},{"issue":"3","key":"21735_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ajur.2017.05.001","volume":"4","author":"HY Ngai","year":"2017","unstructured":"Ngai HY, Yuen KS, Ng CM, Cheng CH, Chu SP. Metabolic syndrome and benign prostatic hyperplasia: An update. Asian J Urol. 2017;4(3):164\u201373.","journal-title":"Asian J Urol"},{"issue":"2","key":"21735_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.juro.2007.03.103","volume":"178","author":"JK Parsons","year":"2007","unstructured":"Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178(2):395\u2013401.","journal-title":"J Urol"},{"issue":"4","key":"21735_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11884-010-0067-2","volume":"5","author":"JK Parsons","year":"2010","unstructured":"Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010;5(4):212\u20138.","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"2","key":"21735_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/oxfordjournals.aje.a009775","volume":"149","author":"EA Platz","year":"1999","unstructured":"Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol. 1999;149(2):106\u201315.","journal-title":"Am J Epidemiol"},{"key":"21735_CR14","doi-asserted-by":"crossref","unstructured":"Ferrari Alize J, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361.","DOI":"10.1016\/S0140-6736(24)00757-8"},{"issue":"1","key":"21735_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12740\/PP\/103876","volume":"54","author":"P Krawczyk","year":"2020","unstructured":"Krawczyk P, \u015awi\u0119cicki \u0141. ICD-11 vs. ICD-10 - a review of updates and novelties introduced in the latest version of the WHO International Classification of Diseases. Psychiatr Pol. 2020;54(1):7\u201320.","journal-title":"Psychiatr Pol."},{"issue":"1","key":"21735_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1478-7954-1-4","volume":"1","author":"JJ Barendregt","year":"2003","unstructured":"Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr. 2003;1(1):4.","journal-title":"Popul Health Metr"},{"key":"21735_CR17","unstructured":"Flaxman AD, Vos T, Murray CJ. An integrative metaregression framework for descriptive epidemiology. (No Title). 2015."},{"issue":"1","key":"21735_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/13685538.2018.1434772","volume":"22","author":"AE Calogero","year":"2019","unstructured":"Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms\/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22(1):12\u20139.","journal-title":"Aging Male"},{"issue":"1\u20132","key":"21735_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cca.2006.01.019","volume":"370","author":"H Nandeesha","year":"2006","unstructured":"Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370(1\u20132):89\u201393.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"21735_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/1008-682X.122341","volume":"16","author":"F Lotti","year":"2014","unstructured":"Lotti F, Corona G, Vignozzi L, Rossi M, Maseroli E, Cipriani S, et al. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl. 2014;16(2):295\u2013304.","journal-title":"Asian J Androl"},{"issue":"21","key":"21735_CR21","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/archinte.166.21.2381","volume":"166","author":"V Kupelian","year":"2006","unstructured":"Kupelian V, Wei JT, O\u2019Leary MP, Kusek JW, Litman HJ, Link CL, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166(21):2381\u20137.","journal-title":"Arch Intern Med"},{"issue":"4","key":"21735_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11934-009-0044-5","volume":"10","author":"AV Sarma","year":"2009","unstructured":"Sarma AV, Kellogg PJ. Diabetes and benign prostatic hyperplasia: emerging clinical connections. Curr Urol Rep. 2009;10(4):267\u201375.","journal-title":"Curr Urol Rep"},{"key":"21735_CR23","first-page":"10","volume":"31","author":"OB Ahmad","year":"2001","unstructured":"Ahmad OB, Boschi Pinto C, Lopez AD. Age Standardization of Rates: A New WHO Standard. GPE Discussion Paper Series: No. 2001;31:10\u20132.","journal-title":"GPE Discussion Paper Series: No"},{"key":"21735_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12963-015-0042-4","volume":"13","author":"JA Haagsma","year":"2015","unstructured":"Haagsma JA, Maertens de Noordhout C, Polinder S, Vos T, Havelaar AH, Cassini A, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr. 2015;13:10.","journal-title":"Popul Health Metr."},{"issue":"11","key":"21735_CR25","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","volume":"3","author":"JA Salomon","year":"2015","unstructured":"Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712\u201323.","journal-title":"Lancet Glob Health"},{"issue":"9859","key":"21735_CR26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129\u201343.","journal-title":"Lancet"},{"issue":"9859","key":"21735_CR27","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163\u201396.","journal-title":"Lancet"},{"issue":"1","key":"21735_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000473711","volume":"29","author":"PP Sagnier","year":"1996","unstructured":"Sagnier PP, Girman CJ, Garraway M, Kumamoto Y, Lieber MM, Richard F, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol. 1996;29(1):15\u201320.","journal-title":"Eur Urol"},{"issue":"2","key":"21735_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0090-4295(01)01506-0","volume":"59","author":"G Welch","year":"2002","unstructured":"Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002;59(2):245\u201350.","journal-title":"Urology"},{"issue":"3","key":"21735_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/iju.12681","volume":"22","author":"Y Bayoud","year":"2015","unstructured":"Bayoud Y, de la Taille A, Ouzzane A, Ploussard G, Allory Y, Yiou R, et al. International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol. 2015;22(3):283\u20137.","journal-title":"Int J Urol"},{"issue":"7","key":"21735_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197818","volume":"13","author":"S Yoo","year":"2018","unstructured":"Yoo S, Park J, Cho SY, Cho MC, Jeong H, Son H. Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria. PLoS ONE. 2018;13(7): e0197818.","journal-title":"PLoS ONE"},{"issue":"6","key":"21735_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.15286","volume":"127","author":"BM Launer","year":"2021","unstructured":"Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127(6):722\u20138.","journal-title":"BJU Int"},{"issue":"1","key":"21735_CR33","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1038\/s41598-017-06628-8","volume":"7","author":"SWH Lee","year":"2017","unstructured":"Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7(1):7984.","journal-title":"Sci Rep"},{"issue":"1","key":"21735_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"GO Collaborators","year":"2017","unstructured":"Collaborators GO. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"21735_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin. 2016;43(3):289\u201397.","journal-title":"Urol Clin"},{"issue":"6","key":"21735_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022792","volume":"9","author":"W Zhang","year":"2019","unstructured":"Zhang W, Zhang X, Li H, Wu F, Wang H, Zhao M, et al. Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH) in China: results from the China Health and Retirement Longitudinal Study. BMJ Open. 2019;9(6): e022792.","journal-title":"BMJ Open"},{"issue":"1","key":"21735_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.31","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai B, Forde JC, Thomas DDM, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2(1):1\u201315.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"21735_CR38","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2016.09.032","volume":"71","author":"P Dahm","year":"2017","unstructured":"Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, et al. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2017;71(4):570\u201381.","journal-title":"Eur Urol"},{"issue":"10258","key":"21735_CR39","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. The lancet. 2020;396(10258):1204\u201322.","journal-title":"The lancet"},{"issue":"5","key":"21735_CR40","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.juro.2008.07.059","volume":"180","author":"JH Fowke","year":"2008","unstructured":"Fowke JH, Murff HJ, Signorello LB, Lund L, Blot WJ. Race and socioeconomic status are independently associated with benign prostatic hyperplasia. J Urol. 2008;180(5):2091\u20136 discussion 6.","journal-title":"J Urol."},{"issue":"11","key":"21735_CR41","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","volume":"3","author":"AF Awedew","year":"2022","unstructured":"Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Healthy Longevity. 2022;3(11):e754\u201376.","journal-title":"The Lancet Healthy Longevity"},{"issue":"2","key":"21735_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/luts.12049","volume":"6","author":"YC Tong","year":"2014","unstructured":"Tong YC. Which Term to Use: BPO or BPH? Low Urin Tract Symptoms. 2014;6(2):129.","journal-title":"Low Urin Tract Symptoms"},{"key":"21735_CR43","doi-asserted-by":"publisher","first-page":"1271816","DOI":"10.3389\/fpubh.2024.1271816","volume":"12","author":"F Alzahrani","year":"2024","unstructured":"Alzahrani F, Madkhali OA, Khardali A, Alqahtani SS, Hijri AM, Alaqil MA, et al. Awareness and prevalence of self-reported benign prostatic hyperplasia: a cross-sectional study in Saudi Arabia. Front Public Health. 2024;12:1271816.","journal-title":"Front Public Health"},{"key":"21735_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fpubh.2020.00231","volume":"8","author":"DJ McMaughan","year":"2020","unstructured":"McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic Status and Access to Healthcare: Interrelated Drivers for Healthy Aging. Front Public Health. 2020;8:231.","journal-title":"Front Public Health"},{"issue":"1","key":"21735_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12939-018-0791-3","volume":"17","author":"V Dei","year":"2018","unstructured":"Dei V, Sebastian MS. Is healthcare really equal for all? Assessing the horizontal and vertical equity in healthcare utilisation among older Ghanaians. Int J Equity Health. 2018;17(1):86.","journal-title":"Int J Equity Health"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-21735-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-21735-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-21735-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:51:59Z","timestamp":1738907519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-21735-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21735"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-21735-2","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was obtained from the Ethics Committee of Tabriz University of Medical Sciences, Tabriz, Iran (IR.SBMU.RETECH.REC.1403.092).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"500"}}